Detail of "162394-19-6"

Reference

Palifermin: a keratinocyte growth factor that reduces oral mucositis after stem cell transplant for hematological malignancies

All Rights Reserved. Palifermin: a keratinocyte growth factor that reduces oral mucositis after stem cell transplant for hematological malignancies. Beaven, Anne W.; Shea, Thomas C. (Hematology/Oncology Fellow, Hematology/Oncology, University of North Carolina, Chapel Hill, NC 27599, USA). Expert Opinion on Pharmacotherapy, 7(16), 2287-2299 (English) 2006 Informa Healthcare. CODEN: EOPHF7. ISSN: 1465-6566. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. 162394-19-6 and 148348-15-6 which are cas registry numbers are also used here. Mucositis occurs in ￡ 98% of patients undergoing stem cell transplant for haematol. malignancies and is assocd. with significant morbidity and mortality. Patients with severe mucositis have more pain, more difficulty with daily activities such as talking and eating, and are more likely to have bacteremia. Palifermin is a keratinocyte growth factor that has been shown to decrease severity and duration of mucositis with a concurrent decrease in patient-reported symptoms and use of narcotics and total parenteral nutrition. Research is ongoing into palifermin's potential ability to decrease graft-vs.-host disease and improve reconstitution of functional T lymphocytes after allogeneic stem cell transplant, to hasten wound healing and to reduce mucositis following external beam radiation therapy in solid tumor patients. .

Effect of renal function on the pharmacokinetics of palifermin

All Rights Reserved. Effect of renal function on the pharmacokinetics of palifermin. Gillespie, B.; Zia-Amirhosseini, P. 148348-15-6 and 162394-19-6 are also occured in this study.; Salfi, M.; Kakkar, T.; Wang, J.; Gupta, S.; Smith, B.; Robson, R.; Sullivan, J. T. (Amgen Inc., Thousand Oaks, CA, USA). Journal of Clinical Pharmacology, 46(12), 1460-1468 (English) 2006 Sage Publications. CODEN: JCPCBR. ISSN: 0091-2700. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Palifermin (DN23KGF) decreases the incidence, severity, and duration of oral mucositis. The objectives of this open-label study were to evaluate the pharmacokinetics of single-dose palifermin in subjects with varying degrees of renal function. A single 90-mcg/kg i.v. dose of palifermin was administered to 31 subjects with varying levels of renal function (normal to requiring hemodialysis). Pharmacokinetic analyses were conducted using serum palifermin concns. There was considerable overlap in mean palifermin serum clearance among the groups, ranging from 318 to 495 mL/h/kg, indicating that the level of renal function did not affect clearance in humans; thus, no dose adjustment of palifermin is indicated for patients with renal dysfunction. .